Target intelligence / Profile preview

Influenza A virus neuraminidase (secondary sialic acid-binding site) (NA-SBS)

Target
NA-SBS
Molecular classification
Enzyme, Viral protein, Glycoside hydrolase family 34
01

Overview

The second sialic acid-binding site (SBS) is a non-catalytic pocket located on the surface of the Influenza A virus neuraminidase (NA) protein, distinct from the primary catalytic site (Vavricka et al., 2011, Nature). While the primary site is responsible for cleaving sialic acid to allow viral release, the SBS facilitates the initial binding and walking of the virus across the sialylated host cell surface and through the mucus layer (Du et al., 2019, J. Virol.). This site is highly conserved in avian influenza viruses (N1, N2, N3, N5, N6, N7, N9) and was present in the 1918 pandemic H1N1 strain, though it has been lost in many subsequent human seasonal lineages (Zhu et al., 2012, Nat. Commun.). Research suggests that the SBS plays a crucial role in viral fitness and host-range adaptation by modulating the balance between hemagglutinin binding and neuraminidase cleavage (Benton et al., 2015, J. Biol. Chem.). As a therapeutic target, the SBS offers a strategy to combat resistance to traditional neuraminidase inhibitors like oseltamivir, which only target the catalytic site (Vavricka et al., 2013, PLOS Pathogens). Experimental multivalent inhibitors designed to bind both the primary and secondary sites have shown promise in neutralizing a broader range of influenza strains by increasing avidity and blocking viral motility (Zhang et al., 2018, Bioconjug. Chem.).

Other names
Secondary sialic acid-binding siteHemagglutinin-like siteNon-catalytic sialic acid-binding site2nd SBSNeuraminidase secondary site
02

Mechanism of action

Inhibition of viral motility and attachment by blocking the non-catalytic sialic acid-binding site on the neuraminidase protein.

03

Biological functions

Viral motilityViral attachmentMucus penetrationViral releaseHemagglutination
04

Disease associations

InfectionInfluenza A
05

Safety considerations

Strain-specific presence (absent in some human seasonal strains)Potential for rapid mutational escapeCross-reactivity with host sialidases
06

Interacting drugs

Multivalent neuraminidase inhibitors (experimental)

1 more in the full profile.

07

Biomarkers

Neuraminidase subtype (e.g., N1, N2, N9)NA sequence motifs (residues 367, 370, 372, 400, 403, 432)Viral hemagglutination titer

Beyond the preview

Go deeper on Influenza A virus neuraminidase (secondary sialic acid-binding site) (NA-SBS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A virus neuraminidase (secondary sialic acid-binding site) (NA-SBS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call